AdvaMed® Statement on President’s Reciprocal Tariff Pause
WASHINGTON – Today AdvaMed, the MedTech Association®, released the following statement from President and CEO Scott Whitaker:
“We are encouraged by the President’s announcement of a 90-day pause on reciprocal tariffs. This is an important decision that restores some short-term certainty to global markets, including the American medtech industry, which is number one globally.
“Moving forward, we will spend the next 90 days working with the President and his senior team to ensure the unique role of the medtech industry is protected, with the hope that the ultimate outcome is ‘zero for zero’ tariffs on medtech with all key trading partners.”
Related Reading
Resource / Digital Health / Government & Legislative Affairs
AdvaMed® 2025 Membership Has Its Privileges: Advocacy Wins for Medtech Members
March 3, 2026
AdvaMed® 2025 Membership Has Its Privileges highlights major legislative and regulatory wins delivering millions in savings and new revenue for members.
Resource / Government & Legislative Affairs
Scott Whitaker Op-Ed: Medicare must keep pace with FDA-authorized breakthrough medical technologies
February 27, 2026
Medicare breakthrough medical technologies face delays between FDA authorization and coverage decisions, slowing patient access to innovation.
Event / Emerging Policy Response Resources / Global & Trade / Government & Legislative Affairs / Supply Chain / Tariffs
Navigating the ACCESS & TEMPO Models: A Direct Dialogue with CMMI & FDA Leaders
March 6, 2026
2:00 PM – 3:00 PM
JoinAdvaMed® for an exclusive member-only webinar featuring a direct dialogue with CMS Innovation Center leadership on the newly released ACCESS Model. Attendees will gain critical insights into model performance metrics, payment pathways, and opportunities for the MedTech industry.
News / Global & Trade / Tariffs
ICYMI: AdvaMed’s Scott Whitaker on Supreme Court Tariffs Decision, Next Steps
February 23, 2026
Scott Whitaker, president and CEO ofAdvaMed®, the world’s largest trade association representing medtech innovators, released the following statement after Fridays’ Supreme Court ruling on tariffs. Today, he published a more fulsome readout on LinkedIn, available here.
Event / Emerging Policy Response Resources / Global & Trade / Government & Legislative Affairs / Supply Chain / Tariffs
The Supreme Court Struck Down IEEPA Tariffs – What Medtech Needs To Know
March 31, 2026
1:00 PM
Now On Demand
Resource / Government & Legislative Affairs / Policy Briefings
AdvaMed® 2026 State Policy Briefing Series
February 23, 2026
Explore the 2026 State Policy Briefing Series for insights on medtech policy, legislative activity, and regulatory updates impacting the medtech industry.
Blog / Diagnostics / Digital Health / Government & Legislative Affairs / Health Access
Heart Month: Why Sleep Apnea Belongs at the Center of Cardiovascular Care
February 13, 2026
February is American Heart Month—a time to spotlight cardiovascular disease and highlight innovations that can improve patient outcomes. For the medtech community, it’s an opportunity to address persistent gaps in care through technology, data, collaboration, and policy advancement. Despite progress in treating heart conditions, sleep disorders—especially sleep apnea—remain a significant and underrecognized contributor to poor cardiovascular outcomes.1 Tackling this issue requires clinical awareness and supportive policies for timely diagnosis, coverage, and care beyond traditional settings.
News / Global & Trade / Supply Chain / Tariffs
AdvaMed® Supports United States-Mexico-Canada Agreement Renewal
February 12, 2026
WASHINGTON—AdvaMed, the MedTech Association®, representing more than 650 medtech and health tech companies, the majority small businesses, today expressed support for renewal of the United States-Mexico-Canada Agreement (USMCA). Scott Whitaker,AdvaMed® president and CEO, made the following comment on the renewal.